Taxus Cardium Pharmaceuticals Performance
| CRXMDelisted Stock | USD 0.0001 0.00 0.00% |
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Taxus Cardium are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Taxus Cardium Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Taxus Cardium is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 400.00 |
Taxus |
Taxus Cardium Relative Risk vs. Return Landscape
If you would invest 0.01 in Taxus Cardium Pharmaceuticals on September 19, 2024 and sell it today you would earn a total of 0.00 from holding Taxus Cardium Pharmaceuticals or generate 0.0% return on investment over 90 days. Taxus Cardium Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Taxus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Taxus Cardium Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Taxus Cardium's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Taxus Cardium Pharmaceuticals, and traders can use it to determine the average amount a Taxus Cardium's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| CRXM |
Based on monthly moving average Taxus Cardium is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Taxus Cardium by adding Taxus Cardium to a well-diversified portfolio.
Taxus Cardium Fundamentals Growth
Taxus Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Taxus Cardium, and Taxus Cardium fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Taxus Pink Sheet performance.
| Return On Asset | -2.62 | |||
| Current Valuation | 881.11 K | |||
| Shares Outstanding | 64.93 M | |||
| Price To Book | 3.36 X | |||
| Price To Sales | 137.13 X | |||
| EBITDA | (458.68 K) | |||
| Cash And Equivalents | 386.03 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 1.26 M | |||
| Debt To Equity | (1.01) % | |||
| Book Value Per Share | (0.1) X | |||
| Cash Flow From Operations | (1.13 M) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 566.98 K | |||
| Retained Earnings | (114.05 M) | |||
| Current Asset | 30.78 K | |||
| Current Liabilities | 3.83 M | |||
About Taxus Cardium Performance
By examining Taxus Cardium's fundamental ratios, stakeholders can obtain critical insights into Taxus Cardium's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Taxus Cardium is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California. Taxus Cardium operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.Things to note about Taxus Cardium Pharma performance evaluation
Checking the ongoing alerts about Taxus Cardium for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Taxus Cardium Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Taxus Cardium Pharma is not yet fully synchronised with the market data | |
| Taxus Cardium Pharma has some characteristics of a very speculative penny stock | |
| Taxus Cardium Pharma has a very high chance of going through financial distress in the upcoming years | |
| Taxus Cardium Pharmaceuticals currently holds 1.26 M in liabilities. Taxus Cardium Pharma has a current ratio of 0.08, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Taxus Cardium until it has trouble settling it off, either with new capital or with free cash flow. So, Taxus Cardium's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Taxus Cardium Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Taxus to invest in growth at high rates of return. When we think about Taxus Cardium's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (517.9 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Taxus Cardium Pharmaceuticals currently holds about 386.03 K in cash with (1.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Taxus Cardium's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Taxus Cardium's stock is overvalued or undervalued compared to its peers.
- Examining Taxus Cardium's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Taxus Cardium's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Taxus Cardium's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Taxus Cardium's pink sheet. These opinions can provide insight into Taxus Cardium's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in Taxus Pink Sheet
If you are still planning to invest in Taxus Cardium Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taxus Cardium's history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |